在抗精神病治疗中添加孕烯醇酮和l -茶氨酸可缓解精神分裂症的阴性和焦虑症状:一项为期8周的随机、双盲、安慰剂对照试验

Q4 Medicine Clinical Schizophrenia and Related Psychoses Pub Date : 2018-01-01 Epub Date: 2015-07-28 DOI:10.3371/CSRP.KARA.070415
Adasa Kardashev, Yael Ratner, Michael S Ritsner
{"title":"在抗精神病治疗中添加孕烯醇酮和l -茶氨酸可缓解精神分裂症的阴性和焦虑症状:一项为期8周的随机、双盲、安慰剂对照试验","authors":"Adasa Kardashev,&nbsp;Yael Ratner,&nbsp;Michael S Ritsner","doi":"10.3371/CSRP.KARA.070415","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Pregnenolone (PREG) and L-theanine (LT) have shown ameliorative effects on various schizophrenia symptoms. This is the first study to evaluate the efficacy and safety of augmentation of antipsychotic treatment among patients with chronic schizophrenia or schizoaffective disorder with PREG-LT.</p><p><strong>Methods: </strong>Double-blind, placebo-controlled trial of PREG-LT or placebo augmentation was conducted for eight weeks with 40 chronic DSM-IV schizophrenia and schizoaffective disorder patients with suboptimal response to antipsychotics. Oral PREG (50 mg/day) with LT (400 mg/day) or placebo were added to a stable regimen of antipsychotic medication from March 2011 to October 2013. The participants were rated using the Scale for the Assessment of Negative Symptoms (SANS), the Hamilton Scale for Anxiety (HAM-A), and the Positive and Negative Syndrome Scale (PANSS) scales bi-weekly. The decrease of SANS and HAM-A scores were the co-primary outcomes. Secondary outcomes included assessments of general functioning and side effects.</p><p><strong>Results: </strong>Negative symptoms such as blunted affect, alogia, and anhedonia (SANS) were found to be significantly improved with moderate effect sizes among patients who received PREG-LT, in comparison with the placebo group. Add-on PREG-LT also significantly associated with a reduction of anxiety scores such as anxious mood, tension, and cardiovascular symptoms (HAM-A), and elevation of general functioning (GAF). Positive symptoms, antipsychotic agents, concomitant drugs, and illness duration did not associate significantly with effect of PREG-LT augmentation. PREG-LT was well-tolerated.</p><p><strong>Conclusions: </strong>Pregnenolone with L-theanine augmentation may offer a new therapeutic strategy for treatment of negative and anxiety symptoms in schizophrenia and schizoaffective disorder. Further studies are warranted.</p><p><strong>Trial registration: </strong>clinicaltrials.gov Identifier: NCT01831986.</p>","PeriodicalId":40019,"journal":{"name":"Clinical Schizophrenia and Related Psychoses","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"15","resultStr":"{\"title\":\"Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.\",\"authors\":\"Adasa Kardashev,&nbsp;Yael Ratner,&nbsp;Michael S Ritsner\",\"doi\":\"10.3371/CSRP.KARA.070415\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Pregnenolone (PREG) and L-theanine (LT) have shown ameliorative effects on various schizophrenia symptoms. This is the first study to evaluate the efficacy and safety of augmentation of antipsychotic treatment among patients with chronic schizophrenia or schizoaffective disorder with PREG-LT.</p><p><strong>Methods: </strong>Double-blind, placebo-controlled trial of PREG-LT or placebo augmentation was conducted for eight weeks with 40 chronic DSM-IV schizophrenia and schizoaffective disorder patients with suboptimal response to antipsychotics. Oral PREG (50 mg/day) with LT (400 mg/day) or placebo were added to a stable regimen of antipsychotic medication from March 2011 to October 2013. The participants were rated using the Scale for the Assessment of Negative Symptoms (SANS), the Hamilton Scale for Anxiety (HAM-A), and the Positive and Negative Syndrome Scale (PANSS) scales bi-weekly. The decrease of SANS and HAM-A scores were the co-primary outcomes. Secondary outcomes included assessments of general functioning and side effects.</p><p><strong>Results: </strong>Negative symptoms such as blunted affect, alogia, and anhedonia (SANS) were found to be significantly improved with moderate effect sizes among patients who received PREG-LT, in comparison with the placebo group. Add-on PREG-LT also significantly associated with a reduction of anxiety scores such as anxious mood, tension, and cardiovascular symptoms (HAM-A), and elevation of general functioning (GAF). Positive symptoms, antipsychotic agents, concomitant drugs, and illness duration did not associate significantly with effect of PREG-LT augmentation. PREG-LT was well-tolerated.</p><p><strong>Conclusions: </strong>Pregnenolone with L-theanine augmentation may offer a new therapeutic strategy for treatment of negative and anxiety symptoms in schizophrenia and schizoaffective disorder. Further studies are warranted.</p><p><strong>Trial registration: </strong>clinicaltrials.gov Identifier: NCT01831986.</p>\",\"PeriodicalId\":40019,\"journal\":{\"name\":\"Clinical Schizophrenia and Related Psychoses\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"15\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Schizophrenia and Related Psychoses\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3371/CSRP.KARA.070415\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2015/7/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Schizophrenia and Related Psychoses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3371/CSRP.KARA.070415","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/7/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 15

摘要

目的:孕烯醇酮(PREG)和l -茶氨酸(LT)对多种精神分裂症症状有改善作用。这是第一个评估慢性精神分裂症或分裂情感性障碍患者使用PREG-LT增强抗精神病药物治疗的有效性和安全性的研究。方法:对40例慢性DSM-IV型精神分裂症和分裂情感性障碍抗精神病药物反应不佳的患者进行为期8周的PREG-LT或安慰剂增强双盲、安慰剂对照试验。从2011年3月至2013年10月,在稳定的抗精神病药物治疗方案中加入口服PREG (50 mg/天)和LT (400 mg/天)或安慰剂。参与者使用阴性症状评估量表(SANS)、汉密尔顿焦虑量表(HAM-A)和阳性和阴性综合征量表(PANSS)进行评分,每两周进行一次。SANS和HAM-A评分的下降是共同的主要结局。次要结局包括一般功能和副作用的评估。结果:与安慰剂组相比,接受PREG-LT的患者的负面症状,如钝化情绪、痛症和快感缺乏(SANS)得到了显著改善,效果中等。附加PREG-LT还与焦虑评分(如焦虑情绪、紧张和心血管症状(HAM-A))的降低以及一般功能(GAF)的升高显著相关。阳性症状、抗精神病药物、伴随药物和病程与PREG-LT增强效果无显著相关性。PREG-LT耐受性良好。结论:孕烯醇酮与l -茶氨酸增强可能为治疗精神分裂症和分裂情感性障碍的阴性和焦虑症状提供一种新的治疗策略。进一步的研究是必要的。试验注册:clinicaltrials.gov标识符:NCT01831986。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.

Aims: Pregnenolone (PREG) and L-theanine (LT) have shown ameliorative effects on various schizophrenia symptoms. This is the first study to evaluate the efficacy and safety of augmentation of antipsychotic treatment among patients with chronic schizophrenia or schizoaffective disorder with PREG-LT.

Methods: Double-blind, placebo-controlled trial of PREG-LT or placebo augmentation was conducted for eight weeks with 40 chronic DSM-IV schizophrenia and schizoaffective disorder patients with suboptimal response to antipsychotics. Oral PREG (50 mg/day) with LT (400 mg/day) or placebo were added to a stable regimen of antipsychotic medication from March 2011 to October 2013. The participants were rated using the Scale for the Assessment of Negative Symptoms (SANS), the Hamilton Scale for Anxiety (HAM-A), and the Positive and Negative Syndrome Scale (PANSS) scales bi-weekly. The decrease of SANS and HAM-A scores were the co-primary outcomes. Secondary outcomes included assessments of general functioning and side effects.

Results: Negative symptoms such as blunted affect, alogia, and anhedonia (SANS) were found to be significantly improved with moderate effect sizes among patients who received PREG-LT, in comparison with the placebo group. Add-on PREG-LT also significantly associated with a reduction of anxiety scores such as anxious mood, tension, and cardiovascular symptoms (HAM-A), and elevation of general functioning (GAF). Positive symptoms, antipsychotic agents, concomitant drugs, and illness duration did not associate significantly with effect of PREG-LT augmentation. PREG-LT was well-tolerated.

Conclusions: Pregnenolone with L-theanine augmentation may offer a new therapeutic strategy for treatment of negative and anxiety symptoms in schizophrenia and schizoaffective disorder. Further studies are warranted.

Trial registration: clinicaltrials.gov Identifier: NCT01831986.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Schizophrenia and Related Psychoses
Clinical Schizophrenia and Related Psychoses Medicine-Psychiatry and Mental Health
自引率
0.00%
发文量
0
期刊介绍: The vision of the exciting new peer-reviewed quarterly publication Clinical Schizophrenia & Related Psychoses (CS) is to provide psychiatrists and other healthcare professionals with the latest research and advances in the diagnosis and treatment of schizophrenia and related psychoses. CS is a practice-oriented publication focused exclusively on the newest research findings, guidelines, treatment protocols, and clinical trials relevant to patient care.
期刊最新文献
Dysexecutive Behavior in First-Episode Schizophrenia. Dysexecutive Behavior in First-Episode Schizophrenia Grading meningiomas by used imaging features on magnetic resonance imaging The Association between Serum Levels of Ferritin and D-Dimer with Liver Function Tests in Patients with COVID-19 Role of Susceptibility Weighted Magnetic Resonance Imaging in Neurological Diagnosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1